As of 3:59pm ET
| +0.005 / +0.27%|
The 2 analysts offering 12-month price forecasts for Transition Therapeutics Inc have a median target of 3.27, with a high estimate of 4.30 and a low estimate of 2.25. The median estimate represents a +73.73% increase from the last price of 1.89.
The current consensus among 2 polled investment analysts is to Buy stock in Transition Therapeutics Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.